The first half of 2021 saw a flurry of IPOs as multiple companies make the move to become publicly traded.

In a flurry of activity, multiple biopharma companies made their first appearance on the Nasdaq Stock Exchange on June 25, raising hundreds of millions of dollars to advance the development of next-generation therapeutics and scale their businesses.

The U.S. Food and Drug Administration rejected Orphazyme’s key drug candidate for Niemann-Pick disease type C (NPC), causing the Denmark-based biopharmaceutical company’s “meme stock” to decline in trading. 

MorphoSys is acquiring Constellation Pharmaceuticals for about $1.7 billion and announced a partnership with Royalty Pharma for $1.425 billion up front.

Boston Scientific will pay $189 million to settle a multi-state lawsuit over the marketing of the company’s surgical mesh devices.

Shares of Pandion Therapeutics soared more than 131 percent in trading after pharma giant Merck announced the acquisition of the autoimmune-focused company for up to $1.85 billion.

Biogen announced the widely awaited submission of a U.S. marketing application for the experimental Alzheimer’s therapy aducanumab, sending the company’s shares up more than 8 percent before the bell.

Neurotrope and Metuchen Pharmaceuticals announced the companies have merged in an all-stock deal to form Petros Pharmaceuticals, which is focused on men’s health conditions.

Shares of Acacia Pharma skyrocketed in trading after the company announced FDA approval for Barhemsys (amisulpride injection) for the prevention and treatment of postoperative nausea and vomiting (PONV) in adults.

Asia reported hundreds of new coronavirus cases – including an American soldier stationed in South Korea – as the United States warned of a pandemic, the disease spread in Europe and Brazil confirmed Latin America’s first infection.